COST-EFFECTIVENESS ANALYSIS OF HISTAMINE DIHYDROCHLORIDE + LOW DOSE INTERLEUKIN-2 VS STANDARD OF CARE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN THEIR FIRST COMPLETE REMISSION- A UK PERSPECTIVE

Author(s)

Magar RS1, Purdy C2, Hayward A2, Einarson TR3, Burnett AK41AHRM Inc., Raleigh, NC, USA, 2AHRM Inc., Buffalo, NY, USA, 3University of Toronto, Toronto, ON, Canada, 4University of Wales College of Medicine, Cardiff, United Kingdom

OBJECTIVES:   To determine the incremental cost-effectiveness of histamine dihydrochloride + low dose interleukin-2 vs standard of care (maintenance therapy) in patients experiencing their first complete remission from AML. METHODS:   Data from a multi-national phase-III clinical trial (129 received drug and 132 standard care) provided rates for remission (leukemia free survival), relapse and death at 5 years.  From the payor perspective, resources consumed (concomitant medications, blood products, emergency room visits, physician visits) were tabulated by treatment arm and assigned a unit cost from UK sources, discounted at 5%. The cost of relapse was estimated from the literature as patients from the clinical trial were not followed once in relapse.  The cost of histamine dihydrochloride (used in conjunction with low dose interleukin-2) was not included in the analysis as no pricing has been established to date.  Estimated drug cost was computed based on ICERs using £30K, £35K and £40K ceiling.  RESULTS:   Five-year Leukemia Free Survival (LFS) for drug and standard of care was 2.23 vs 1.75 years (P=0.02), respectively.  Mean cost/patient treated was £40,209 with treatment and £41,702 with standard care, which includes IL-2 cost (£3,600) for the complete 10 cycles.  To compute the maximum cost of histamine dihydrochloride, ICERs were computed with £30K, £35K and £40K ceilings, to estimate acquisition costs for patients who receive all 10 treatment cycles.  Acquisition costs were £24,265, £27,928 and, £31,592, respectively.  CONCLUSIONS:  Maintenance therapy with histamine dihydrochloride + low dose interleukin-2 vs standard care for patients in their first complete remission from AML provides approximately 0.5 years more of LFS and can be done cost-effectively if acquisition costs are below reasonable thresholds. Increased LFS also reduces relapse rates, further contributing to cost savings.

Conference/Value in Health Info

2009-10, ISPOR Europe 2009, Paris, France

Value in Health, Vol. 12, No. 7 (October 2009)

Code

PCN83

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×